FoxM1 mediated resistance to gefitinib in non-smallcell lung cancer cells
Authors:
- Xun WangXWXun Wang
- Xiao-Ying WangXWXiao-Ying Wang
- Chun-Xue BaiCBChun-Xue Bai
- 26 March 2012
- journal article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 33 (5) , 675-681
Abstract
Aim: Methods: Results: Conclusion:Keywords
This publication has 35 references indexed in Scilit:
- Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxolBMC Cancer, 2008
- Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid TumorsAnnals of Pharmacotherapy, 2006
- Increased Levels of the FoxM1 Transcription Factor Accelerate Development and Progression of Prostate Carcinomas in both TRAMP and LADY Transgenic MiceCancer Research, 2006
- Forkhead Box M1 Regulates the Transcriptional Network of Genes Essential for Mitotic Progression and Genes Encoding the SCF (Skp2-Cks1) Ubiquitin LigaseMolecular and Cellular Biology, 2005
- Resistance to epidermal growth factor receptor-targeted therapyDrug Resistance Updates, 2005
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- The Akt-mTOR tango and its relevance to cancerCancer Cell, 2005
- Loss of the Forkhead Transcription Factor FoxM1 Causes Centrosome Amplification and Mitotic CatastropheCancer Research, 2005
- Survivin as a Radioresistance Factor, and Prognostic and Therapeutic Target for Radiotherapy in Rectal CancerCancer Research, 2005
- FoxM1 is required for execution of the mitotic programme and chromosome stabilityNature Cell Biology, 2005